



Cancer Metastasis and its Suppressor Genes

Raja Ramesh G.V*

Department of Biochemistry, GITAM University, Andhra Pradesh, India

*Corresponding author: Department of Biochemistry, GITAM Institute of Science, GITAM University, Andhra Pradesh, India, E-mail: rajaramesh369@gmail.com

Received: February 07, 2017; Accepted: March 25, 2017; Published: April 03, 2017

Abstract

Cancer is type of disease involves abnormal growth of cell. It can easily transmit & forms tumors to one organ to another organ. Metastasis is the spread of a cancer or other disease from one organ or part of the body. Metastasis is the spread of cancer cells to new areas of the body. Through metastasis the cancer cells are spreading to the different parts of the body through the blood and lymph nodes. Tumors formed from cells that have spread are called secondary tumors. The cancer may have spread to areas near the primary site is regional metastasis and to parts of the body that are farther away is distant metastasis. So it is also called as the 4th stage of the cancer.

Keywords: Metastasis; Tumor; Suppressor genes; Breast cancer

Introduction

Metastasis is a complex process, which spread the cancer from one organ to another without any direct contact. It requires the regulation of both metastasis-promoting and metastasis suppressor genes [1-5]. Firstly lymph node are affected early, then for the lungs, liver, brain and bones are the most common metastasis locations. It shows some symptoms and also cause pain but it is not the first symptom. Sometimes the effected person do not show any symptoms but the effected organ begin to shrink until its lymph node undergo lysis or burst [6-12].

Metastasis can spread through blood or lymphatic system or both routes.

Spreading routes:

1. Lymphatic Spread: Through lymph nodes and it is most common route for carcinomas.
2. Hematogenous Spread: Typical route for sarcomas, originating from kidney – renal cell carcinoma.
3. Transcoelomic: It is through penetrating the surface of peritoneal, pericardial, pleural and subarachnoid spaces.

Ovarian tumors can spread to the surface of the liver.

After the tumor cells come to rest at another site and they penetrate into another vessel and multiply forming another tumor. This new tumor is known as a metastatic (or) secondary tumor. Metastasis is one of the "Hallmarks of Cancer". Metastasis cancer is also called as 4th stage of cancer because its spread regionally to lymph nodes, tissues or organs and it can also

spread to distant parts of the body [13-19]. We cannot cure the cancer but we have the potentiality to reduce the fatality rate of the effected person. Major methods are of surgery, radiation and chemotherapy.

People can gain the knowledge and know the information thorough Open access journals. It provide more information and accessibility to the readers in gaining the required information [20-26].

To create awareness among the people, researchers and scientists together form a society. The main aim of these societies is to visualize and create awareness to people and also sharing the knowledge to the world.

Open access journals in Cancer share the recent and scientific research publications to the society. Journal of Cancer Science & Therapy provides information on recent therapeutic techniques used to reduce the cancer. Chemotherapy: Open Access is a open access journal which publishes high quality articles to improve the knowledge and provide chemotherapy techniques which are used in the present world. Cancer Surgery, Advances in Cancer Prevention, Breast Cancer: Current Research, Cancer Medicine & Anti-Cancer Drugs, Journal of Cancer Science & Therapy, Journal of Cancer Diagnosis gives more information globally, sharing preventive and diagnosis methods. Some upcoming conferences are going to discuss their ideas on cancer therapy which is 19th Euro Congress on Cancer Science and Therapy on July 17-19, 2017. Some are aimed to sharing the information and debate in conferences through Cancer Therapy, Biomarkers & Clinical Research. Some of the speakers explored new ideas and motivate the conference in young researchers through their speech in 25th World Cancer Conference. Some of the journals have high prowess members they are actively participating as Editor-in-chief are Maria Jose Molina Garrido and Steven D Wexner are having high importance their research work. High professional people will share the knowledge and their ideas to visualize the young researchers in the world through the journals [27-33].

Metastasis Suppressor Genes

Metastasis Suppressor is a protein that helps to prevent metastases. It is one of the lethal cancer process. Metastasis suppressors were first identified using a microcell-mediated chromosome transfer (MMCT) [34-39]. It is a technique to transfer a chromosome from a donor to recipient cell line. When compared with tumor suppressor, metastatic suppressor act by different mechanisms. However it do not affect the primary tumors. Chromosomes 1, 6, 7, 8, 10, 11, 12, 16, and 17 were found to harbor metastasis suppressors [40-46]. The discovery of metastasis suppressor genes is helps to understanding the metastasis mechanism and provide prognostic markers and therapeutic targets to cure the cancer clinically.

MicroRNAs (miRNAs) are a class of gene regulators that bind the 3' untranslated regions of target messenger RNAs, leading to either suppression of their translation or acceleration of their degradation. In the cell MDA-MB-231 (established from a pleural effusion of a 51 year old woman with metastatic breast cancer) and its metastatic variant, contains 6 miRNAs. In that miR-335 and miR-126 suppress metastasis without effecting the primary tumor growth. miR-335 targets multiple pathways (SOX4), which helps the metastatic suppression [47-53]. But in breast cancer – miR-335 expression is correlated to metastasis free survival.

Genes

Metastasis-suppressing genes (proteins) are identified in humans and other animals, including BRMS1, CRSP3, DRG1, KAI1, KISS1, NM23 and various TIMPs [54-59]. Most act by altering aspects of signal transduction. Decreased expression of the suppressor gene is the key parameter determining metastatic potential and may occur by a variety of mechanisms. nm23 (NME1) and KAI1 are the best characterized metastatic suppressor genes [60-68].

NM23

NME1 nucleoside diphosphate kinase 1 is an enzyme which is a metastatic suppressor. It was identified in 1988 as the first metastatic suppressor due to its reduced mRNA transcript levels in highly metastatic cells [69-76]. It exists as a hexamer composed of 'A' (encoded by this gene) and 'B' (encoded by NME2) isoforms. Mutations in this gene have been identified in aggressive neuroblastomas.

NM23 is a suppressor active in melanoma, breast and colon cancers and apparently inhibits the functioning of a kinase enzyme that promotes cell division. It is having eight family members NM23-H1 – NM23-H8 [77-82]. Among this NM23-H1 and NM23-H2 suppress metastasis in multiple tumor types. NM23 expression can serve as a potential prognostic marker for survival in breast, ovarian, melanoma, gastric, hepatocellular and non-small cell carcinoma. It affects the MAPK (Mitogen-activated protein kinase) and cytoskeleton-organizing cellular pathways [83-88].

Most of the metastasis suppressors are downregulated in clinical tumor samples rather than mutated. Metastasis suppressors have potentiality to block metastasis and improve the survival of the affected person when the suppressor genes are activated. NM23 promoter region contains glucocorticoid response elements that can elevate the NM23 expression [89-95]. Dexamethasone medroxyprogesterone acetate (MPA) can have the ability to increase NM23 expression. It is used in treating human breast cancer.

KAI1

KAI1 is a metastatic suppressor gene located on human chromosome 11, belongs to the family of cell surface glycoproteins. It is found in prostate and breast cancers [96-99]. It forms complexes with proteins called integrins and it will link cells together. The complex formation may inhibit detachment and migration of cancer cells.

Decreased KAI1 expression has been observed in several common solid epithelial tumors, including prostatic, pancreatic, lung, hepatic, colorectal, ovarian, and esophageal cancers. In recent study observed that by using immunohistochemical technique we can know the frequent loss of KAI1 expression in a number of squamous cell carcinomas [100-102].

Conclusion

Metastasis is always coincide or depends on the primary cancer i.e., where the tumor is started from a cancer cell. Different types of metastasis suppressor genes are identified in both humans and animals. Those genes are only suppress the metastasis process in a limit time but not the entire time. Methods such as radiotherapy, chemotherapy, anticancer drugs can only increase the life span of the affected person but not to decrease the cancer cells.

REFERENCE

1. Sinha BK. Nitric Oxide: Friend or Foe in Cancer Chemotherapy and Drug Resistance: A Perspective. J Cancer Sci Ther. 2016;8(10):244-251.
2. Bisen PS. Nutritional Therapy as a Potent Alternate to Chemotherapy against Cancer. J Cancer Sci Ther. 2016;8(6):e135.

3. Baram A, Tayeb ZA. Mediastinal Masses: Retrospective Single Center Based Study. *J Cancer Sci Ther.* 2016;8(10):252-256.
4. Rihan FA, Rihan NF. Dynamics of Cancer-Immune System with External Treatment and Optimal Control. *J Cancer Sci Ther.* 2016;8(10):257-261.
5. Khalid A, Javaid MA. Matrix Metalloproteinases: New Targets in Cancer Therapy. *J Cancer Sci Ther.* 2016;8(6):143-153.
6. Fazari ABE, Mohammed WARM, Gailii EBM, et al. Squamous Cell Carcinoma in a Mutilated Vulva: A Case Report. *J Cancer Sci Ther.* 2015;7(3):093-094 Wu RL, Ali S, Sarkar FH, et al. Identification of Differentially Expressed Mirnas in Appendiceal Mucinous Cystadenocarcinoma from Mucinous Cystadenoma. *J Cancer Sci Ther.* 2015;7(11):328-335.
7. Geleta B, Makonnen E, Abay SM. N-myc Downstream Regulated Gene (NDRG): Role in Cancer Metastasis Suppression and as Drug Target in Cancer Therapeutics. *J Cancer Sci Ther.* 2016;8(6):154-159.
8. Reyad D, Zekri J, Farag K, et al. Hyponatremia and SIADH Frequency in Clinically Euvolemic Patients Receiving Chemotherapy: Prospective Study in Unselected Patients' Cohort. *J Cancer Sci Ther.* 2016;8(6):055-058.
9. Geleta B, Makonnen E, Abay SM. Cyclic Dependent Kinase (CDK): Role in Cancer Pathogenesis and as Drug Target in Cancer Therapeutics. *J Cancer Sci Ther.* 2016;8(6):160-167.
10. Fazioli F, Colella G, Camerlingo R, et al. Silicate Granules Preconditioned with Human Bone Marrow Mononuclear Cells Improve Osteogenesis in Bone Sarcoma Patients. *J Cancer Sci Ther.* 2015;7(11):321-327.
11. Ali S, Dubaybo H, Brand RE, et al. Differential Expression of Micrnas in Tissues and Plasma Co-exists as a Biomarker for Pancreatic Cancer. *J Cancer Sci Ther.* 2015;7(11):336-346.
12. Singh V, Gupta D, Almasan A. Development of Novel Anti- Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response. *J Cancer Sci Ther.* 2015;7(11):347-358.
13. Sur D, Chakravorty R. Present Status of Cervical Neoplasia Control and Human Papilloma Virus Epidemiology in India: The Wind is Blowing; Unfolding the Truth. *J Cancer Sci Ther.* 2015;7(11):363-366.
14. Hamzawy MA, Abo-youssef AM, Salem HF, et al. An Additional risk of Lung Cancer from Recurrent Exposure to Ethyl Carbamate (EC) in BALB/C Mice. *J Cancer Sci Ther.* 2015;7(11):359-362 Kumar KS, Sastry N, Polaki H, et al. Colon Cancer Prevention through Probiotics: An Overview. *J Cancer Sci Ther.* 2015;7(3):081-092.
15. Murugan NJ, Karbowski LM, Dotta BT, et al. Differentiation of Malignant Compared to Non-Malignant Cells by Their Bio- Photon Emissions May Only Require a Specific Filter around 500 nm. *J Cancer Sci Ther.* 2016;8(6):168-169 Bourton EC, Hussain H, Plowman PN, et al. Radiosensitivity of Human Breast Cancer Cell Lines Expressing the Breast Tumor Kinase (Brk). *J Cancer Sci Ther.* 2015(3)7:095-101.
16. Uddin MH, Kim B, Suh DH, et al. Anticancer Strategy Targeting Mitochondrial Biogenesis in Ovarian Cancer. *J Cancer Sci Ther.* 2014;6(10):422-428.
17. Pistelli M, Pagliacci A, Ballatore Z, et al. Using of Androgen Receptor Expression as a Novel Potential Biomarker in Predicting Survival of Women with Metastatic Triple Negative Breast Cancer. *J Cancer Sci Ther.* 2014;6(10):388-393.
18. Gresta LT, Júnior IAR, Cabral MMDÁ. Microvessel Density Quantification in Gastric Cancer: Comparing Methods for Standard Measures. *J Cancer Sci Ther.* 2014;6(10):401-405.

19. Osman MAA, Hamid ME, Satti AH, et al. High Concentration of Tumor Marker Cancer Antigen CA15-3 in Breast Cancer Patients after Surgery. *Breast Can Curr Res.* 2016;1(4):114.
20. Blighe K, Beauchamp N, Allen KE, et al. Next Generation Sequencing in the National Health Service England: A Pipeline that Completely Agrees with Sanger. *J Cancer Sci Ther.* 2014;6(10):406-410.
21. Lampe CM, Gondi CS. Cathepsin B Inhibitors for Targeted Cancer Therapy. *J Cancer Sci Ther.* 2014;6(10):417-421.
22. Rahmani S, Brown J, Gendy R. The Clinical and Histopathological Significance of Performing Surgical Cavity Random Biopsy in Breast Conserving Surgery on Disease Course and Local Recurrence. *Breast Can Curr Res.* 2016;1(2):104.
23. Sandra SH, Mahmoud AE, John AC, et al. Pleomorphic Lobular Carcinoma of the Breast: A Review of 35 Cases at a Single Institution . *Breast Can Curr Res.* 2016;1(2):105.
24. Meredith I, Goh J, Gerred S. Mammographic Surveillance after Breast Reconstruction-Is Imaging Necessary?. *Breast Can Curr Res.* 2016;1(2):106.
25. Güler G, Çelik A. 2,3,7,8-Tetrachlorodibenzo-p-dioxin: Genotoxicity and Oxidative Damage Potential in Human Peripheral Blood Lymphocytes. *J Carcinog Mutagen.* 2016;7(5):274.
26. Pathak P, Guha S, Vidya V, et al. Comparative Analysis of Dose Variations in Tumor Volumes and Organs at Risk in IMRT Plans for Head-And-Neck, Pelvis and Brain Cancers with Varying Dose Calculation Grid Sizes. *J Cancer Sci Ther.* 2014;6(10):394-400.
27. Blair S, Robles J, Weiss A, et al. Treatment of Breast Cancer in Women Aged 80 and Older: A Systematic Review. *Breast Can Curr Res.* 2016;1(4):115.
28. Kinoshita S, Fukushima N, et al. Clinicopathological Assessment of Patients with Locally Advanced Breast Cancer with 10 or More Lymph Node Metastases. *Breast Can Curr Res.* 2016;1(2):107.
29. Gratzke AL, Reimers K, Vogt PM, et al. Sensitising Breast Cancer Cells to Chemotherapy by Down Regulation of Lifeguard. *J Cancer Sci Ther.* 2014;6(10):411-416.
30. Aymen FA, Atef Y, Majed G, et al. Axillary Masse, is it an Ectopic Mammary Gland?. *Breast Can Curr Res.* 2016;1(2):108.
31. El Hadj OEA, Chaar I, Goucha A, et al. Pure Micropapillary Carcinoma of the Male Breast: Report of A Rare Case. *Breast Can Curr Res.* 2016;1(4):113.
32. Puckett Y, Abedi M, Alavi-Dunn N, et al. Does Offering Free Breast Cancer Screenings Make a Difference?– A Retrospective 3-Year-Review of a West Texas Free Breast Cancer Screening Program. *J Cancer Diagn.* 2016;1(1):101.
33. Villabona CV, Mohan V, Arce KM, et al. Utility of Ultrasound vs. Gene Expression Classifier in Thyroid Nodules with Atypia of Undetermined Significance. *J Cancer Diagn.* 2016;1(1):103.
34. Raquel CC, Aurora LV. Delaying Radiotherapy and Risk of Recurrences in Patients with Breast Cancer Stage I And II. A Retrospective Observational Study. *Breast Can Curr Res.* 2016;1(4):116.
35. Vohra LM, Siddiqui T. Metaplastic Breast Cancer and p16 Positivity: What Does It Mean?. *J Carcinog Mutagen.* 2015;6(6):244.
36. Nna EO, Tothill S, Bailey T. Allelic Variants of KLK2 Gene Predict Presence of Prostate Cancer at Biopsy. *J Cancer Diagn.* 2016;1(1):105.

37. Ozturk O. Significance of Primary Care Healthcare Services in the Early Detection of Cancer. *Can Surg.* 2016;1(2):107.
38. Kayar Y, Kayar NB, Ekinici I, et al. Multiple Myeloma Relapsed with Skull Involvement in Plasmacytoma. *J Carcinog Mutagen.* 2016;7(5):273.
39. Jatawa SK, Tiwari A. Evaluation of Microsatellite Instability and Apoptosis in Gall Bladder Malignancy from Patients of a Cohort Exposed to Methylisocyanate. *J Carcinog Mutagen.* 2014;5(3):171
40. Alnuqaydan AM, Lenehan CE, Hughes RR, et al. Calendula officinalis Extracts Protect against H2O2 Induced Chromosome Damage on HacaT Human Skin Cells. *J Carcinog Mutagen.* 2015;6(6):245.
41. Durak ZE, Kocaoglu H, AđubukAđu HC, et al. Echinacea Inhibits Adenosine Deaminase Enzyme in Cancerous Human Gastric Tissue. *J Carcinog Mutagen.* 2015;6(6):246.
42. Tadesse SK. Preventive Mechanisms and Treatment of Cervical Cancer in Ethiopia. *Cervical Cancer.* 2016;1(1):101
43. Bragazzi NL, Spera R, Pechkova E, et al. NAPPA-Based Nanobiosensors for the Detection of Proteins and of Protein-Protein Interactions Relevant to Cancer. *J Carcinog & Mutagen.* 2014;5(3):166.
43. Syeed N, Hamali HAA, Alahmari KA, et al. Molecular Enhancers; Remote Controls the Differential Gene Expression during Development. *J Carcinog & Mutagen.* 2014;5(3):168.
44. Zhang M, He J, Yang J. Targeting Human β -Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment. *Chemo Open Access.* 2016;5(2):190.
45. Cheng C, Shi L. Irinotecan-Based Regimen as Second-Line Chemotherapy for Extensive-Stage Small Cell Lung Cancer. *J Cancer Diagn.* 2016;1(1):102.
46. Sun Y, Beattie J, Mogal H, et al. Neoadjuvant Vemurafenib for Borderline Resectable Metastatic Melanoma to Liver: A Case Report. *J Carcinog Mutagen.* 2016;5(3):169.
47. Ranchal I, de Castro ML, Muntané J. Olive Leaves and Mill Waste Exert Anti-Tumoral Properties in Hepatoma Cell Line. *J Carcinog Mutagen.* 20014;5(3):170.
48. Davidson BA, Nagel CI, Richardson DL. Skin Metastases to Cesarean Scar at Diagnosis of Carcinoma of Cervix in a Postpartum Female. *Cervical Cancer.* 2016;1(1):102.
49. Fedele M, Cerchia L, Chiappetta G. The Tumor Suppressive Role of PATZ1 in Thyroid Cancer: A Matter of Epithelial-Mesenchymal Transition. *Chemo Open Access.* 2016;5(2):198.
50. Kubo A, Tsukiyama I, Tsukiyama S, et al. NK-1 Receptor Antagonists: Who Truly Need them and their Cost-Effectiveness Analysis?. *Chemo Open Access.* 2016;5(2):197.
51. Sarwar A, Suri J, Sharma V, et al. Novel Benchmark Database of Digitized and Calibrated Cervical Cells for Artificial Intelligence Based Screening of Cervical Cancer. *Cervical Cancer.* 2016;1(1):105.
52. Laviada DI, Velasco G, Henche NR, et al. Emerging Role of the Peroxisome Proliferator-Activated Receptors in Hepatocellular Carcinoma. *J Carcinog Mutagen.* 2014;5(3):167.
53. Elgohary H, Oraby E, Zidan A, et al. Spared Healthy Breast Tissue after Breast Conserving Surgery for Palpable Invasive Ductal Breast Carcinoma; US Guided Versus Traditional Palpation Guided Excision. *Can Surg.* 2016;1(2):106.
54. Uddin G, Rauf A, Siddiqui BS, et al. Broad Spectrum Anticancer Activity of Pistagremic Acid. *Chemotherapy.* 2013;2(2):117.

55. Cheng H, Huang C, Qiu H, et al. A New Mutation Identified in an Imatinib and Nilotinib Resistant Chronic Myeloid Leukemia Patient. *Chemo Open Access*. 2016;5(2):193.
56. Principe M, Cappello P, Novelli F. Blockade of Surface Alpha-Enolase (ENO1) as a Novel Immunotherapeutic Approach in Pancreatic Cancer. *Chemo Open Access*. 2016;5(2):188.
57. Kotb AF, Attia D. Correlation between the Presentation of Renal Cell Carcinoma and its Prognosis. *J Clin Exp Oncol*. 2015;4(1).
58. Heidari A. A Chemotherapeutic and Biospectroscopic Investigation of the Interaction of Double-Standard DNA/RNA-Binding Molecules with Cadmium Oxide (CdO) and Rhodium (III) Oxide (Rh₂O₃) Nanoparticles as Anti-Cancer Drugs for Cancer Cells' Treatment. *Chemo Open Access*. 2016;5(2):e129.
59. Rastogi R, Meena GL, Wani AM, et al. Rectal Carcinoma with Osteosclerotic Metastases-A Rare Occurrence. *J Cancer Diagn*. 2016;1(1):104.
60. Clemente N, Alessandrini L, Giorda G, et al. Enterouterine Fistula as Initial Presentation of Advanced Endometrial Cancer: Description of a Rare Case and Review of the Literature. *J Clin Exp Oncol*. 2016;5(6).
61. Abate SM. Trends of Cervical Cancer in Ethiopia. *Cervical Cancer*. 2016;1(1):103.
62. Bagella L, Marchesi I. SFK Inhibitors as New Strategy for RMS Treatment. *Chemo Open Access*. 2016;5(2):189.
63. Di Agostino S, Blandino G. Genomic Instability: The Pivotal Role of Mutant p53 in Human Cancers. *Chemo Open Access*. 2016;5(2):191.
64. Ullah E, Nagi AH, Ashraf M, et al. Prognostic Role of Microvascular Density and Mucin Production in 56 Cases of Adenocarcinoma of Lung- An Experience from a Center in Lahore, Pakistan. *Chemo Open Access*. 2016;5(2):194.
65. Malik AA, Kiran T. Psychological Problems in Breast Cancer Patients: A Review. *Chemotherapy*. 2013;2(2):115.
66. AbdAllah AAA, Hummeida ME, Elmula IMF. Awareness and Attitudes of Nursing Students towards Prevention of Cervical Cancer. *Cervical Cancer*. 2016;1(1):106.
67. Lucibello M, De Braud F. Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast Cancer. *Chemo Open Access*. 2016;5(2):196.
68. Mushtaq M. Choriocarcinoma Presenting as Intracerebral Haemorrhage and No Evident Primary: Rare Presentation. *J Clin Exp Oncol*. 2015;4(1).
69. Dong J, Liu, Zhu R. Targeting ROS for Cancer Therapy. *Chemo Open Access*. 2016;5(2):199.
70. Zhu HH, Liu YR, Qin YZ. CD34-Negative is Highly Associated with T (15;17), T (V; 11q23) and the NPM1-Mutation Subtypes in 343 Newly Diagnosed Patients with Acute Myeloid Leukemia . *Chemo Open Access*. 2016;5(2):200.
71. Zhu M, Li W, Dong X , et al. Alpha Fetoprotein Plays Antagonistic Role in Benzyl-Isothiocyanate Arresting Cell Cycle in Liver Cancer Cells. *Chemo Open Access*. 2016;5(2):195.
72. Yang H, Chen L, Chen Y, et al. FBXW7 Pathway Functions as a Promising Therapeutic Target of Cholangiocarcinoma. *Chemo Open Access*. 2016;5(2):201.
73. Wang Y, Cui W, Wen J, et al. Raltitrexed based Transcatheter Arterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma: A Single-center Randomized Controlled Study. *Chemo Open Access*. 2016;5(2):192.
74. Robak T. Staging and Prognostic Factors in Chronic Lymphocytic Leukemia: Current Status. *J Leuk (Los Angel)*. 2014;2(5):e111.

75. Xu Y, Herrmann J, Pellikka PA, et al. Early Changes in 2D-Speckle-Tracking Echocardiography may Predict a Decrease in Left Ventricular Ejection Fraction in Lymphoma Patients Undergoing Anthracycline Chemotherapy: A Pilot Study. *J Clin Exp Oncol.* 2015;4(1).
76. Gumustas SA, Yilmaz I, Isyar M, et al. Is it Possible to Expedite Studies on the Effects of Pharmacological Agents on Primary Cell Cultures Obtained from High-grade Fibular Osteosarcoma? *J Clin Exp Oncol.* 2016;5(6).
77. Suliman OAA, Aidarous T, Marglani O, et al. Diagnostic and Therapeutic Challenges in IgG4-Related disease in the Sphenoid Sinus. *J Clin Exp Oncol.* 2015;4(1).
78. Farzanfar H, Motalleb G, Maghsoudi H. VEGF Expression Evaluation in Patients with Esophageal Cancer by using Reverse Transcriptase Real- Time Polymerase Chain Reaction. *J Clin Exp Oncol.* 2016;5(6)
79. Albrecht AM, Yang J, Li M. Combinational Treatment for Pancreatic Cancer: Where Are We Standing? *J Clin Exp Oncol.* 2012;1(1).
80. Rosko AE, McColl KS, Zhong F, et al. Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl- 2 Family Member Expression in CLL Cells: Potential Implications for the CLL Microenvironment. *J Leuk (Los Angel).* 2014;2(5):160.
81. Hayashibara N, Ogawa T, Tsuji E, et al. Parathyroid Carcinoma Coincident With Neurofibromatosis Type 1. *J Clin Exp Oncol.* 2016;5(6).
82. Yonemura Y, Canbay E, Endou Y, et al. Mechanisms of the Formation of Peritoneal Surface Malignancy on Omental Milky Spots from Low Grade Appendiceal Mucinous Carcinoma. *J Clin Exp Oncol.* 2014;3(4).
83. Saurabh K, Scherzer MT, Song A, et al. Dissecting the In Vivo Leukemogenic Potency of Bclxl. *J Leuk (Los Angel).* 2014;2(5):158.
84. El-Abaseri TB, El-Metwally TH, Iversen PL, et al. Inhibition of Cytochrome P450 and Multidrug Resistance Proteins Potentiates the Efficacy of All-Trans Retinoic Acid in Pancreatic Cancer In Vitro and In Vivo. *J Clin Exp Oncol.* 2015;4(1).
85. Rathod GB, Parmar P, Rathod S, et al. Tumoral Calcinosis on Right Knee in 26 Years Old Male: A Rare Case Report. *J Clin Exp Oncol.* 2014;3(4).
86. Maurice Efana Asuquo. Skin Malignancies. *J Clin Exp Oncol.* 2012;1(1).
87. Santanu Dasgupta. Mitochondrial Insult and Revenge in Tumorigenesis. *J Clin Exp Oncol.* 2012;1(1).
88. Rodrigues C, Romeira D, Pinto M, et al. Immunosurveillance in Colorectal Carcinomas with Microsatellite Instability. *J Clin Exp Oncol.* 2017;6(1).
89. Reisman DN, Marquez S. Biomarkers Can Promote Risk Stratification in CT Scanning for Lung Cancer Detection. *J Clin Exp Oncol.* 2012;1(1).
90. Frank R, Sadri N, Bhatti T, et al. Proximal-type Epithelioid Sarcoma of the Head and Neck (HN): A Study with Immunohistochemical and Molecular Analysis of SMARCB1. *J Clin Exp Oncol.* 2013;2(2)
91. An Pham T, Zhao Y, Sigston E. Schwannoma of the Palatine Tonsil: A Rare Entity in an Eight Year Old Girl. *J Clin Exp Oncol.* 2013;2(2).
92. Coyne CP, Jones T, Bear R. Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma. *J Clin Exp Oncol.* 2013;2(2).

93. Malone MV, Mejía EH, Hu G. Lack of Association between Angiogenin (AGN) KO Mice with Improvement in Muscle Strength, Resistance, but Decreased in Chances of Tumorigenesis: Observational Study. *J Clin Exp Oncol.* 2017;6(1).
94. Marfe G, Stefano CD. Cancer Stem Cells in Chronic Myelogenous Leukemia. *J Leuk (Los Angel).* 2014;2(5):159.
95. Akodu SO, Abideen MG, Adediji UO. Ganglioneuroblastoma of the Cerebellum: A Case Report. *J Clin Exp Oncol.* 2014;3(4).
96. Dombi P, Andrikovics H, Illés Á, et al. Thromboembolic Events in Polycythaemia Vera Patients: An Audit of the Hungarian Philadelphia Negative Chronic Myeloproliferative Neoplasia Register. *J Clin Exp Oncol.* 2017;6(1).
97. Hassoun HK, Al-Essawi S, Tiraihi TA, et al. Can Medulloblastoma be Presented with Primary Diffuse Leptomeningeal Gliomatosis? Case Report and Literature Review. *J Clin Exp Oncol.* 2017;6(1).
98. Maite LD, Ricardo GC, Ilde ZA, et al. Atipic Axillary Mass: Follicular Dendritic Cell Sarcoma within Castleman's Disease: A Case Report and Review of Literature. *J Clin Exp Oncol.* 2014;3(4).
99. Seyedmajidi M, Foroughi R. Central Mucoepidermoid Carcinoma—A Case Report and Review of the Literature. *J Clin Exp Oncol.* 2013;2(2).
100. Shin DG, Kim KC, Choi S, et al. A Methylation Profile of Circulating Cell Free DNA for the Early Detection of Gastric Cancer and the Effects after Surgical Resection. *J Clin Exp Oncol.* 2015;5(1).
101. Kheir V, Xavier Borruat F. Cotton Wool Spots in Trousseau's Syndrome. *J Clin Exp Oncol.* 2015;5(1).
102. Guest TC, Rashid S. Anticancer Laccases: A Review. *J Clin Exp Oncol.* 2016;5(1).